文献速递哮喘

抗IL-5生物制剂治疗哮喘患者合并铜绿假单胞菌感染时出现高嗜酸性粒细胞血症

Hypereosinophilia With Pseudomonas aeruginosa Infection in Patients With Asthma on Anti-Inteleurkin-5 Biologics.
PubMed 文献 · Chest · 2026-01-01

本文报告2例接受美泊利珠单抗或贝那利珠单抗治疗的严重哮喘患者,在急性加重期出现嗜酸性粒细胞反弹升高(分别为1,400 cells/μL和1,690 cells/μL),均与铜绿假单胞菌气道感染相关,经抗生素治疗后缓解。提示铜绿假单胞菌可能通过不依赖IL-5的机制驱动嗜酸性粒细胞增多,抗IL-5/IL-5R治疗期间加重时应考虑痰培养。

要点

  • 抗IL-5/IL-5R治疗期间嗜酸性粒细胞反弹需警惕铜绿假单胞菌感染。
  • 铜绿假单胞菌可能通过不依赖IL-5的机制驱动嗜酸性粒细胞增多。
  • 哮喘加重接受抗IL-5/IL-5R治疗者应查痰培养,不论2型生物标志物水平。

核心结论

  • 铜绿假单胞菌气道感染可能与抗IL-5/IL-5R治疗的哮喘患者嗜酸性粒细胞反弹相关,经抗假单胞菌治疗后可缓解。

研究设计与样本

  • 病例报告,共2例接受美泊利珠单抗或贝那利珠单抗治疗的严重哮喘患者。

主要发现

  • 病例1为加拿大71岁女性,严重嗜酸性哮喘合并慢阻肺重叠,美泊利珠单抗治疗期间急性加重时嗜酸性粒细胞反弹至1,400 cells/μL,伴铜绿假单胞菌感染,抗生素治疗后缓解。
  • 病例2为英国56岁女性,迟发型哮喘,贝那利珠单抗治疗期间嗜酸性粒细胞显著反弹至1,690 cells/μL,伴铜绿假单胞菌感染,抗假单胞菌治疗后缓解。

临床怎么用

  • 接受抗IL-5或IL-5R治疗的哮喘患者急性加重时,应考虑行痰培养,不论2型生物标志物水平。
  • 嗜酸性粒细胞反弹不一定是生物制剂失败,需排查铜绿假单胞菌等感染因素。

局限性

  • 仅为2例病例报告,不能确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biologic therapies targeting IL-5 or its receptor reduce eosinophilia and exacerbations in asthma. Breakthrough eosinophilic attacks are usually considered biologic failure. We report 2 patients with severe asthma receiving mepolizumab or benralizumab who developed relapsing hypereosinophilia associated with Pseudomonas aeruginosa airway infection. Case 1 was a 71-year-old woman in Canada with severe eosinophilic asthma and COPD overlap whose eosinophils suddenly rebounded to 1,400 cells/μL during an acute exacerbation while on mepolizumab, coinciding with P aeruginosa infection and resolving after antibiotic treatment. Case 2 was a 56-year-old woman in the United Kingdom with late-onset asthma who developed marked eosinophil rebound (1,690 cells/μL) during benralizumab therapy, again associated with Paeruginosa infection and resolving after antipseudomonal therapy. These cases suggest that P aeruginosa may drive eosinophilia through IL-5-independent mechanisms. Sputum cultures should be considered during exacerbations in patients treated with anti-IL-5 or IL-5R therapies, regardless of type 2 biomarkers.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Rivard, Mailhot-Larouche, Borg, et al. Hypereosinophilia With Pseudomonas aeruginosa Infection in Patients With Asthma on Anti-Inteleurkin-5 Biologics. Chest. 2026. PMID: 42419852. doi:10.1016/j.chest.2026.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。